Compare GOCO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOCO | ALLR |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 19.3M |
| IPO Year | 2020 | 2021 |
| Metric | GOCO | ALLR |
|---|---|---|
| Price | $1.14 | $1.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.75 | ★ $9.75 |
| AVG Volume (30 Days) | 53.5K | ★ 120.8K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $361,845,000.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $77.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.77 |
| 52 Week High | $10.56 | $2.35 |
| Indicator | GOCO | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 63.51 |
| Support Level | $1.00 | $1.00 |
| Resistance Level | $1.35 | $1.42 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 49.28 | 76.70 |
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions, so it can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. The proprietary technology platform integrates artificial intelligence and modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.